Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET
Company Participants
Juan Sanchez - VP, Corporate Communications & IR
Sharon Mates - Founder, Chairman and CEO
Mark Neumann - EVP and CCO
Sanjeev Narula - CFO
Suresh Durgam - EVP and CMO
Conference Call Participants
Andrew Tsai - Jefferies
Jessica Fye - JPMorgan
Charles Duncan - Cantor
Jason Gerberry - Bank of America Securities
Jeff Hung - Morgan Stanley
Michael DiFiore - Evercore
David Amsellem - Piper Sandler
Joel Beatty - Baird
Corinne Johnson - Goldman Sachs
Operator
Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would like now to hand the call over to Juan Sanchez, Head of Investor Relations. Please go ahead.
Juan Sanchez
Good morning and thank you all for joining us on our third quarter 2024 earnings call. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Chief Commercial Officer; Dr. Suresh Durgam, Chief Medical Officer; and Sanjeev Narula, Chief Financial Officer.
A slide deck to complement today's call is available under the Investors Events section of our corporate website.
During today's call, we will be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions, and expectations. Those statements are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.
These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual
- Read more current ITCI analysis and news
- View all earnings call transcripts